The struggle is real: The first half of 2023 was an uphill climb
Release Date:
Guests Karen Carey, BioWorld’s managing editor, and Mike Ward, Clarivate’s global head of Life Sciences and Healthcare Thought Leadership, discuss the deals, financing and M&A landscape for the first half of 2023 and how U.K. biopharmas are faring post Brexit.
The struggle is real: The first half of 2023 was an uphill climb